Companies › Neuracle Science
1 active drug program in 1 registered trial: 1 Phase 1; Other.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| NS101 anti-FAM19A5 antibody; synapse organizer and reverser of synapse dysfunction | FAM19A5 | Phase 1 | Seneorineural Deafness | – |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06249919 | NS101 | Phase 1 | Seneorineural Deafness | Other | May 2026 |
–
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.